瘤性病毒对SIRPα-Fc的表达通过瘤微环境重编程增强了抗瘤功效
Qingzhe Yang1, Yongheng Shu1, Yanwei Chen1
1Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Frontiers in immunology
|March 12, 2025
概括
工程化瘤性腺病毒 (oAdVs) 表达SIRPα-mIgG1Fc (oAd-SA) 增强了巨细胞细胞和T细胞功能. 这种新型免疫疗法在临床前模型中显示出优异的瘤回归,为全身癌症治疗提供了一个有前途的战略.
科学领域:
- 瘤治疗性病毒疗法
- 癌症免疫疗法癌症免疫疗法
- 瘤微环境调制
背景情况:
- 瘤病毒 (OV) 提供向的癌细胞杀死和免疫刺激.
- 目前的OV输送,主要是内注射,限制了系统癌症的疗效.
- 瘤性腺病毒 (oAdVs) 由于安全性和稳定性而受到广泛研究.
研究的目的:
- 为了设计一个修改的oAdV载体 (pDC316-oAd-SA),表达SIRPα-mIgG1Fc以重塑瘤相关巨细胞 (TAM).
- 评估oAd-SA在体外和体内抗瘤功效.
- 评估oAd-SA对巨细胞化和T细胞免疫功能在瘤微环境中的影响.
主要方法:
- 改造的oAdV矢量 (pDC316-oAd-SA) 的工程,以表达SIRPα-mIgG1Fc.
- 在体外和体内对oAd-SA和对照病毒 (Ad-ON) 的评估.
- 在小鼠瘤模型中评估巨细胞化,T细胞透和免疫功能.
主要成果:
- 与对照组相比,oAd-SA显著增强了巨细胞细胞形成.
- 修改后的oAdV在临床前模型中显示出优异的瘤回归.
- oAd-SA改善了T细胞的透,并特别增强了T细胞的免疫功能.
- 在不同类型的瘤中,oAdVs以不同的方式调节了TAMs,oAd-SA促进了抗瘤反应.
结论:
- 设计的oAd-SA载体有效地重塑TAM,增强抗瘤免疫力.
- oAd-SA显示出作为系统性癌症治疗策略的巨大潜力.
- 用oAdVs针对TAM是改善癌症免疫治疗结果的有希望的途径.
相关概念视频
Tumor Immunotherapy
457
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
Rous Sarcoma Virus (RSV) and Cancer
4.9K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
4.9K
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Mechanisms of Retrovirus-induced Cancers
5.0K
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
5.0K
The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K


